Abstract: Dermatomyositis is an idiopathic myopathy involving progressive muscle weakness with skin manifestation. Diagnosis is based upon the progressive muscle weakness, skin rashes, elevated serum muscle enzymes, muscle biopsy, and abnormal electromyogram. The incidence of dermatomyositis is rare. In this case study, we report a case of classical dermatomyositis without incidence of malignancy. Timely diagnosis and administration of steroid led to better prognosis of the patient.
Introduction
Dermatomyositis (DM), a connective tissue disorder, is an idiopathic inflammatory myopathy characterized by skin manifestation. It occurs in both juvenile and adult forms. The prevalence of dermatomyositis is 1 in 100,000 while women are more affected than men. 1, 2 The diagnosis of dermatomyositis is based on rashes on the skin, progressive muscle weakness, elevated serum muscle enzymes, abnormal electromyogram, and abnormal findings on muscle biopsy. 3 Dermatomyositis has a typical cutaneous feature such as erythema over the face, neck, and upper trunk as "neck-line V-shaped." 4 Photosensitivity and pruritis are other common cutaneous symptoms. Muscle symptoms include mild to severe weakness, muscle cramps, and fatigue. Dyspnea, dysphagia, and weight loss are frequent signs of disease progression or underlying malignancy. 4 To the best of our knowledge no cases are reported from Nepal to date. There are no typical signs and symptoms for the diagnosis of dermatomyositis. We reported a female patient with the features of dermatomyositis.
Case Description
A 44-year-old female patient living in Purano-baneshwor, Kathmandu, Nepal was referred from the National Center for Rheumatic disease (NCRD) for laboratory investigation in the Modern Diagnostic Laboratory and Research Center on 24 July 2019, presenting with hyperpigmented erythematous rash all over her body along with V-shaped rashes on the neckline since 2 months. Initial symptoms as mentioned by the patient included itchy rashes and photosensitivity. She had no history of headache, fever, and weight loss with a normal vital test. In addition, she had no surgical as well as medical history of chronic disease. She had progressed symptoms like muscle pain (especially in the left arm and thigh), unable to walk upstairs, inability to stretch hands, unable to turn neck, and difficulty in swallowing food. anti-Mi-2 antibody are highly specific to dermatomyositis. Based on the above findings, a diagnosis of dermatomyositis was made. She was administered with 50 mg prednisolone with a significant improvement of muscular activities within a month; with a modest fall in serum creatinine kinase level as shown in Table 3 and 25 mg azathioprine once a day as immunosuppressive drugs. At present, she is orally administered 50 mg prednisolone therapy for maintenance therapy and still being followed up. 
Discussion
Dermatomyositis is classified into classical dermatomyositis, amyopathic dermatomyositis, juvenile dermatomyositis, hypomyopathic dermatomyositis, clinically amyopathic dermatomyositis, and clinical lyamyopathic evolving into classic. 5 The patient showed cutaneous manifestation with evidence of myalgia occurring within 1 month after the onset of skin disease, which is classical dermatomyositis. In the older age group, the incidence of malignancy is higher in dermatomyositis. The common malignancies are ovarian cancer, colon cancer, melanoma, breast cancer, and nonHodgkin's lymphoma, while in the Asian population nasopharyngeal cancer is common. 6 The patient showed typical features for diagnosis of dermatomyositis such as progressive muscle weakness, elevated muscle enzyme, dysphagia, and erythematous rashes all over the body with positive anti-Mi-2 antibody, which is specific to dermatomyositis. Treatment is based on highdose prednisolone until clinical and biochemical remission is obtained. Initially, CPK levels were higher; however, on treatment with steroid, the patient responded well and the CPK level reduced significantly, 7 which is similar to our study represented in Table 3 . Decrease in the level of CPK is a good prognostic factor in dermatomyositis patients. 8 Mi-2 antigen, nuclear helicase protein, forms part of the nucleosome remodeling deacetylase (NuRD) complex involved in transcription regulation. 9 Mi-2 is expressed highly in developing hair follicles and embryonic ectoderm, which plays a critical role in the development of epidermis. 10 Mi-2 is also essential for differentiation and renewal of the basal epidermis. 11 Immune response to Mi-2 protein leads to the development of skin rashes and production of anti-mi-2 antibody. 12 Anti-Mi-2 is associated with typical skin manifestation where ultraviolet radiation intensity may have an important role in initiating the disease. Sunlight plays a significant role in anti-Mi-2 production through subcellular distribution, expression, and metabolism of the components of Mi-2 antigens. 13 Mi-2 expression is regulated by UV radiation through protein translation and stability. 14 A patient with anti-Mi -2 antibody presents cutaneous lesions and mild to moderate muscle involvement and responds well to glucocorticoid therapy. Our patient did not have any evidence of malignancy and showed better prognosis. However, recurrence of disease is rare but rashes on skin and retractable myositis can occur, and monitoring and follow-up are needed for the patients. 15 This dermatomyositis patient showed typical clinical manifestation with increased muscle enzymes along with increased liver enzymes. Anti-Mi-2 antibody positive, the patient showed less evidence of malignancy. Proper management and therapy leads to better prognosis of the disease.
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